Immunovant (NASDAQ:IMVT) versus Genocea Biosciences (NASDAQ:GNCAQ) Head-To-Head Comparison

Genocea Biosciences (NASDAQ:GNCAQ) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Insider and Institutional Ownership

47.1% of Immunovant shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 4.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Genocea Biosciences and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Immunovant	N/A	-57.97%	-52.47%

Analyst Ratings

This is a breakdown of current recommendations for Genocea Biosciences and Immunovant, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	N/A
Immunovant	0	0	17	0	3.00

Immunovant has a consensus target price of $48.00, indicating a potential upside of 67.01%.

Volatility & Risk

Genocea Biosciences has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Valuation and Earnings

This table compares Genocea Biosciences and Immunovant’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.64 million	N/A	-$33.20 million	N/A	N/A
Immunovant	N/A	N/A	-$210.96 million	($1.84)	-15.62

Genocea Biosciences has higher revenue and earnings than Immunovant.

Summary

Genocea Biosciences beats Immunovant on 5 of the 8 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.